DURECT’s lead asset, Larsucosterol, is an epigenetic modulator with FDA Breakthrough Therapy Designation Potential to be the first FDA-approved therapeutic option for the treatment of patients with alcoholic hepatitis Proposed… Read More
Combination therapy has potential to be an all-oral, fixed-duration regimen for previously untreated patients with CLL Application is supported by data from the Phase 3 AMPLIFY trial that showed statistically… Read More
VANCOUVER, BC – Acuitas Therapeutics announced the publication of a new study in Genome Biology, titled “Predicting adenine base editing efficiencies in different cellular contexts by deep learning,” demonstrating a… Read More
Second antibody-drug conjugate (ADC) to progress into clinical development utilizing our proprietary payload and optimized antibody Preclinical results demonstrate strong anti-tumor activity and favorable tolerability profile Phase 1 clinical trial… Read More
Every day, patients lose limbs to preventable complications—often without ever receiving proper vascular testing. Now, a new partnership between Providence Health Care Ventures (PHC Ventures) and Moonrise Medical aims to change that… Read More
